Rehan Ishaque

Dr. Rehan Ishaque

orcid

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 April 2026 in Clinical Cardiology
Verified
Journal Article
Open access
RIRehan Ishaque
Rehan Ishaque
GAGeorge S. Abela
George S. Abela
GIGhazal Ishaque
Ghazal Ishaque
AAAmina Akram
Amina Akram
FRF. N. U. Reya
F. N. U. Reya
SRSupratik Rayamajhi
Supratik Rayamajhi
Introduction: Right ventricular pacing (RVP) has long been the standard therapy for bradyarrhythmias but may induce ventricular dyssynchrony and adverse cardiac remodeling. Physiologic pacing strategies that preserve the native conduction system, particularly left bundle branch area pacing (LBBAP), have emerged as promising alternatives. This study aimed to evaluate the comparative efficacy and safety of LBBAP versus RVP through an updated meta‐analysis. Methods: Following PRISMA guidelines, we systematically searched PubMed, Cochrane CENTRAL, and ClinicalTrials.gov for relevant studies published through June 2025. Studies comparing LBBAP and RVP in patients undergoing pacemaker implantation were included. Pooled estimates were calculated using random‐effects models. Results: A total of 40 studies comprising 8290 patients were included. LBBAP was associated with significantly shorter QRS duration compared with RVP (30 studies, n = 5510; MD −35.56 ms, 95% CI −41.88 to −29.24; p < 0.0001). Structural remodeling also favored LBBAP, with greater improvement in left ventricular ejection fraction (16 studies, n = 1693; MD +3.77%, 95% CI 2.43–5.12; p < 0.0001) and greater reduction in left ventricular end‐diastolic diameter (13 studies, n = 1666; MD −2.33 mm, 95% CI −3.59 to −1.07; p < 0.0001). Clinically, LBBAP was associated with lower heart failure hospitalization (RR 0.38, 95% CI 0.29–0.52; p < 0.0001) and reduced all‐cause mortality (RR 0.55, 95% CI 0.41–0.72; p < 0.0001), along with greater reduction in NT‐proBNP levels. Conclusion: LBBAP provides superior electrical synchrony, improved cardiac remodeling, and favorable clinical outcomes compared with RVP, while maintaining a comparable procedural safety profile.

1 January 2026 in Clinical and Applied Thrombosis/Hemostasis
Verified
Journal Article
Open access
RIRehan Ishaque
Rehan Ishaque
ATAbdul Subhan Talpur
Abdul Subhan Talpur
HMHuda Memon
Huda Memon
LALaksh Ahuja
Laksh Ahuja
FRFnu Reya
Fnu Reya
SRSupratik Rayamajhi
Supratik Rayamajhi
Introduction: Hemophilia A and B are among the most common inherited bleeding disorders in humans with lifelong risk of spontaneous and recurrent bleeding. While prophylaxis with clotting factors has improved outcomes, challenges like inhibitor development and treatment burden persist. We aim for a comparative effectiveness between these agents and traditional therapy with this study. Methods: A systematic review and meta-analysis of randomized controlled trials (RCTs) was conducted. Studies were identified through PubMed, Cochrane Central, and ClinicalTrials.gov up to May 30th, 2025. Eligible studies were double-arm RCTs comparing non-clotting factor prophylaxis (emicizumab, fitusiran, concizumab) and on-demand therapy in patients with hemophilia A or B. Results: Non-clotting factor prophylaxis significantly reduced the annualized bleeding rate (ABR) for all treated bleeds [ n = 399, (RR = 0.13; 95% CI: 0.09–0.19), I 2 = 63.8%, p = 0.0107], spontaneous bleeds [RR = 0.08; 95% CI: (0.06, 0.11), I 2 = 0.0%, p = 0.5933)] and joint bleeds [RR = 0.09; 95% CI: (0.06, 0.14), : I 2 = 26.2%, p = 0.2468 ]. Haem-A-QoL total score improved with prophylaxis [MD = −11.08 [−16.34, −5.83], I 2 = 57.5%, p = 0.0949]. Prophylaxis increased the likelihood of achieving zero treated bleeds [RR = 4.11; 95% CI: (1.48%, 11.45%), I 2 = 88.5%, p < 0.0001]. An exploratory network meta-analysis comparing fitusiran, emicizumab, and concizumab reported no statistically significant difference in the ABR for all treated bleeds. Conclusion: Compared to on-demand therapy, non-factor prophylactic therapies significantly reduce bleeding episodes, improve quality of life, and increase the likelihood of zero bleeds in patients with hemophilia.

24 February 2026 in eJHaem
Verified
Journal Article
Open access
RIRehan Ishaque
Rehan Ishaque
ATAbdul Subhan Talpur
Abdul Subhan Talpur
HSHafiza Sidra
Hafiza Sidra
HMHuda Memon
Huda Memon
FMFurqan Tarique Memon
Furqan Tarique Memon
SRSupratik Rayamajhi
Supratik Rayamajhi
Introduction: Paroxysmal nocturnal haemoglobinuria (PNH) is an uncommon, life‐threatening disease, caused by intravascular haemolysis by the complement system. In this review, we aim to compare the efficacy of the available agents across patient‐centred outcomes in complement inhibitor‐naive patients. Methods: Following PRISMA guidelines, a comprehensive literature search was conducted on PubMed, Cochrane CENTRAL and ClinicalTrials.gov for studies published up to 30th May 2025. A frequentist model network meta‐analyses were conducted in RStudio (v5.4.1) using a common‐effects model. Results: A total of four randomized controlled trials evaluating four complement inhibitor agents (ravulizumab, crovalimab, eculizumab and pegcetacoplan) were included in this systematic review and network meta‐analysis, involving 589 complement inhibitor–naïve adults with PNH. Across outcomes, all active treatments demonstrated benefit compared with placebo or supportive care. In the exploratory network meta‐analysis of transfusion avoidance, no consistent statistically significant differences were observed between active treatments, although ravulizumab showed higher odds compared with crovalimab (OR = 2.69, 95% CI: 1.13–6.41; p = 0.0256). For change in FACIT‐Fatigue score, all active treatments improved fatigue versus placebo, with some statistically significant differences observed between agents; however, these comparisons were based on indirect evidence from a sparse network. Conclusion: This study suggests that available complement inhibitors improve key outcomes versus placebo/supportive care in complement inhibitors naive PNH. However, the evidence network is sparse (four trials) and the cross‐trial differences limit reliable inference regarding relative efficacy between active agents. Comparative findings should be interpreted as hypothesis‐generating.

12 August 2026 in Acta Neurologica Belgica
Verified
Journal Article
Closed access
PDF file
MEMohammed Raed Elsaadouni
Mohammed Raed Elsaadouni
NANorah Hani Aldekhail
Norah Hani Aldekhail
AAAbdulla Taher Ahmed Alhawamdeh
Abdulla Taher Ahmed Alhawamdeh
RERaghad Mohamed Eljoujou
Raghad Mohamed Eljoujou
YAYousef Maher Almashhrawi
Yousef Maher Almashhrawi
RIRehan Ishaque
Rehan Ishaque

15 July 2025 in Research Square
Verified
Preprint
Open access
PDF file
Samiullah ShaikhSamiullah Shaikh
Samiullah Shaikh
SSSidra Samad
Sidra Samad
KBKinza Bakht
Kinza Bakht
AMArun Maloth
Arun Maloth
ADAllah Dad
Allah Dad
ABAdnan Bhat
Adnan Bhat
Purpose: Chemotherapy-induced neutropenia (CIN) is a common complication that increases the risk of infection, hospitalization, and treatment delays. While granulocyte colony-stimulating factors (G-CSFs) like filgrastim and pegfilgrastim are used to reduce these risks, limitations in dosing schedules and variability remain. Efbemalenograstim alfa (F-627), a novel long-acting recombinant G-CSF, has emerged as a potential alternative. This systematic review and meta-analysis aimed to evaluate its comparative safety and efficacy against standard G-CSFs in patients undergoing chemotherapy for non-myeloid malignancies. Methods: A comprehensive literature search was conducted across six databases for randomised controlled trials (RCTs) comparing F-627 to standard G-CSFs. Data from three active-controlled trials were pooled using Review Manager (RevMan) 5.4.1, with results expressed as risk ratios (RR) for dichotomous outcomes and mean differences (MD) for continuous outcomes. Heterogeneity was assessed using the I² statistic. Narrative synthesis was performed for the data in the placebo-controlled trial and outcomes with insufficient data for meta-analysis. Risk of bias and evidence quality were evaluated using the Cochrane RoB 2.0 tool and GRADE guidelines, respectively. Results: Four RCTs comprising 973 patients were included, with 533 receiving F-627. F-627 showed comparable efficacy to standard G-CSFs in reducing duration of Grade 4 neutropenia in cycle 1 (MD = 0.04 days; 95% CI: − 0.04 to 0.13; I² = 0%). Incidence of severe neutropenia and febrile neutropenia were also similar (RR = 1.02; 95% CI: 0.97–1.07 and RR = 1.33; 95% CI: 0.41–4.30, respectively). However, a placebo-controlled trial showed a significant reduction in neutropenia and febrile neutropenia incidence with F-627. Secondary outcomes and adverse event profiles were broadly comparable across treatment arms. Conclusion Efbemalenograstim alfa offers a comparable safety and efficacy profile to standard G-CSFs for the prevention of CIN, supporting its role as a viable therapeutic option in non-myeloid cancers.

12 September 2026 in Journal of International Medical Research
Verified
Journal Article
Open access
YSYahya Samadi
Yahya Samadi
ZAZeeshan Ajmal
Zeeshan Ajmal
RIRehan Ishaque
Rehan Ishaque
AMAlaa Abdulrahman Mohammed
Alaa Abdulrahman Mohammed
KIKhizar Irshad
Khizar Irshad
NSNour Ayman Shehabaldin
Nour Ayman Shehabaldin
Objectives: Vulvovaginal candidiasis and its recurrent vulvovaginal candidiasis form place a significant burden on women worldwide. However, treatment options remain limited. Oteseconazole, a first-in-class tetrazole CYP51 inhibitor that received Food and Drug Administration approval for recurrent vulvovaginal candidiasis in 2022, has not yet had its comparative efficacy against fluconazole in acute vulvovaginal candidiasis systematically synthesized. In addition, the full scope of evidence for its maintenance use has not been formally synthesized. Using a dual-Population–Intervention–Comparator–Outcome (PICO) framework, this systematic review and meta-analysis aimed to: (a) evaluate whether oteseconazole provides superior efficacy to fluconazole in acute vulvovaginal candidiasis; (b) comprehensively synthesize maintenance efficacy and safety outcomes in recurrent vulvovaginal candidiasis; and (c) assess the certainty and sufficiency of the available evidence using Grading of Recommendations Assessment, Development, and Evaluation and trial sequential analysis. Methods: This systematic review and meta-analysis was prospectively registered with PROSPERO (registration number: CRD420261331936). A systematic search of PubMed, Embase, Cochrane CENTRAL, and ClinicalTrials.gov was conducted without date or language restrictions. Risk of bias was assessed using the Cochrane Risk of Bias 2.0 tool. Meta-analyses were performed using random-effects models with restricted maximum likelihood estimation and Hartung–Knapp–Sidik–Jonkman correction. Results: A total of five unique randomized controlled trials (six PICO-level inclusions) were included, enrolling 596 participants across PICO 1 and 1090 across PICO 2. In acute vulvovaginal candidiasis (PICO 1, two trials, n = 361), oteseconazole was associated with a significantly higher therapeutic cure rate (composite clinical and mycological cure) at day 28 than fluconazole (risk ratio = 1.39, 95% confidence interval: 1.13 to 1.71; p = 0.002). Significant improvements were also observed in clinical cure at day 28 (risk ratio = 1.28, 95% confidence interval: 1.09 to 1.51; p = 0.003) and mycological cure at both day 14 (risk ratio = 1.24, 95% confidence interval: 1.09 to 1.41; p = 0.001) and day 28 (risk ratio = 1.38, 95% confidence interval: 1.20 to 1.58; p < 0.001). In recurrent vulvovaginal candidiasis prevention (PICO 2, four trials, n = 959), oteseconazole significantly reduced culture-confirmed recurrence at weeks 48–50 (risk ratio = 0.13, 95% confidence interval: 0.09 to 0.19) and week 24 (risk ratio = 0.10, 95% confidence interval: 0.07 to 0.15) and substantially prolonged the time to first recurrence (hazard ratio = 0.09, 95% confidence interval: 0.05 to 0.14), all with zero heterogeneity. Furthermore, trial sequential analysis confirmed that the cumulative evidence surpassed the required information size for both recurrence time points. Safety outcomes were comparable between groups in both settings. Conclusions: In patients with recurrent vulvovaginal candidiasis, oteseconazole demonstrated favorable outcomes by significantly reducing recurrent infections while maintaining a comparable safety profile, supporting its use as a maintenance regimen. However, the evidence supporting its role in acute vulvovaginal candidiasis remains limited.